What do systematic reviews say?

Fluoxetine vs Crocus sativus

It is very uncertain whether fluoxetine changes failure to respond (reduction ≥ 50% on HDRS) compared with crocus sativus (very low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.53 [0.11, 2.6]
  1 study · 40 participants
  Very low

Fluoxetine vs Crocus sativus

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fluoxetine vs Crocus sativus

It is very uncertain whether fluoxetine changes failure to complete ‐ total ‐ compared with crocus sativus (very low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1 [0.06, 17.18]
  1 study · 40 participants
  Very low

Fluoxetine vs Crocus sativus

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fluoxetine vs tricyclic antidepressants (TCAs)

Fluoxetine probably leads to lower failure to complete ‐ side effects ‐ compared with TCAs (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.55 [0.4, 0.75]
  40 studies · 3647 participants
  Moderate

Fluoxetine vs Crocus sativus

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fluoxetine vs duloxetine

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with duloxetine (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.41 [0.61, 3.25]
  1 study · 103 participants
  Low

Fluoxetine vs duloxetine

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fluoxetine vs duloxetine

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with duloxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.9 [0.53, 1.52]
  2 studies · 532 participants
  Moderate

Fluoxetine vs duloxetine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with duloxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 3.33 [0.93, 12.11]
  2 studies · 432 participants
  Moderate

Fluoxetine vs duloxetine

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with duloxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.28 [0.07, 1.23]
  2 studies · 532 participants
  Moderate

Fluoxetine vs escitalopram

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with escitalopram (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.02 [0.56, 1.85]
  1 study · 240 participants
  Low

Fluoxetine vs escitalopram

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 231 participants
  Low

Fluoxetine vs escitalopram

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with escitalopram (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.53 [1, 2.37]
  2 studies · 578 participants
  Moderate

Fluoxetine vs escitalopram

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with escitalopram (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.74 [0.46, 6.53]
  2 studies · 578 participants
  Moderate

Fluoxetine vs tricyclic antidepressants (TCAs)

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with TCAs (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.29 [0.96, 1.72]
  33 studies · 2911 participants
  Moderate

Fluoxetine vs escitalopram

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with escitalopram (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.17 [0.64, 2.12]
  2 studies · 578 participants
  Moderate

Fluoxetine vs fluvoxamine

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with fluvoxamine (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.95 [0.52, 1.74]
  1 study · 177 participants
  Low

Fluoxetine vs fluvoxamine

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fluoxetine vs fluvoxamine

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with fluvoxamine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 71 [0.36, 1.37]
  2 studies · 284 participants
  Moderate